The priority goal of Pharmasyntez is openness and accessibility of information about manufacture and company operation in general. The company annually takes part in meetings with patient communities and is open to dialogue outside special events.
As a part of the meeting, representatives of non-profit organizations visited the Pharmasyntez plant where antitubercular, antiviral, antineoplastic, and antifungal drugs are produced.
Members of the patient community visited three Irkutsk plant workshops manufacturing high demand drugs for the treatment of infectious diseases such as Remdeform (INN: Remdesivir), Kalidavir (INN: Lopinavir + Ritonavir) and other drugs for the treatment of HIV infection.
Pharmasyntez’ representatives discussed with the guests issues related to pricing, registration, and quality and also shared the company's plans to launch new drugs and new forms for the treatment of HIV infection.
To ask questions about the quality of our products or send an adverse effect report:
-
call the 24/7 Pharmasyntez pharmacovigilance hotline at 8 800 100-15-50 (toll free within Russia),
-
fill out one of the forms on this page, or
____
ECAT (Eurasian Community for Access to Treatment) — association of activists and experts for access to the diagnostics and treatment of HIV infection, viral hepatitis, tuberculosis, and cancer.